Pfizer Partners with Sciwind on $495M China Weight Loss and Diabetes Deal
Pfizer has entered a partnership with Hangzhou Sciwind Biosciences to commercialize its next-generation weight management and diabetes therapy in China under a deal valued at up to $495 million for Sciwind. The collaboration grants Sciwind milestone payments and royalties, accelerating Pfizer’s metabolic franchise expansion in the Chinese market.
1. Partnership Terms
Pfizer China and Hangzhou Sciwind Biosciences have agreed to collaborate on the commercialization of Pfizer’s new-generation weight management and diabetes therapy in mainland China. Under the pact, Sciwind will receive up to $495 million in milestone payments plus tiered royalties on net sales of the treatment.
2. Strategic Rationale
The alliance aims to leverage Sciwind’s local regulatory and distribution capabilities to accelerate market entry, while allowing Pfizer to bolster its metabolic disease portfolio in one of the world’s fastest-growing obesity and diabetes markets.